A5013869733- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Respiratory viral infections research
- Influenza Virus Research Studies
- Extracellular vesicles in disease
- SARS-CoV-2 and COVID-19 Research
- Virus-based gene therapy research
- Nanoplatforms for cancer theranostics
- Histone Deacetylase Inhibitors Research
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Herpesvirus Infections and Treatments
- RNA Interference and Gene Delivery
- T-cell and B-cell Immunology
- Metabolism, Diabetes, and Cancer
Metaclipse Therapeutics (United States)
2019-2024
Background PD-L1 is one of the major immune checkpoints which limits effectiveness antitumor immunity. Blockade PD-L1/PD-1 has been a improvement in treatment certain cancers, however, response rate to checkpoint blockade remains low suggesting need for new therapies. Metformin emerged as potential drug cancer due its effects on expression, T cell responses, and immunosuppressive environment within tumors. While benefits metformin combination with have reported animal models, little known...
Triple-negative breast cancer (TNBC) afflicts women at a younger age than other cancers and is associated with worse clinical outcome. This poor outcome attributed to lack of defined targets patient-to-patient heterogeneity in target antigens immune responses. To address such heterogeneity, we tested the efficacy personalized vaccination approach for treatment TNBC using 4T1 murine model. We isolated tumor membrane vesicles (TMVs) from homogenized tissue incorporated glycosyl...
Immune checkpoint inhibitor (ICI) immunotherapy improved the survival of head and neck squamous cell carcinoma (HNSCC) patients. However, more than 80% patients are still resistant to this therapy. To test whether efficacy ICI therapy can be by vaccine-induced immunity, we investigated a tumor membrane-based vaccine in murine models HNSCC. The tumors, grown subcutaneously, used prepare membrane vesicles (TMVs). TMVs then incorporated with glycolipid-anchored immunostimulatory molecules...
Abstract Background Current influenza vaccines deliver satisfactory results in young people but are less effective the elderly. Development of for an ever-increasing aging population has been arduous challenge due to immunosenescence that impairs immune response aged, both quantitatively and qualitatively. Results To potentially enhance vaccine efficacy elderly, we investigated immunogenicity cross-protection hemagglutinin virus-like particles (HA-VLP) incorporated with...
Abstract Several approaches have produced an effective vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the influence of immune responses induced by other vaccinations on durability and efficacy response to SARS-CoV-2 is still unknown. We developed a hybrid for influenza viruses using virus-like particles (VLP) incorporated protein transfer with glycosylphosphatidylinositol (GPI)-anchored S1 RBD fused GM-CSF as adjuvant. GPI-RBD-GM-CSF fusion was...
Dendritic cells (DCs) are the most effective antigen presenting for development of T cell responses. The only FDA approved DC-based immunotherapy to date is Sipuleucel-T, which utilizes a fusion protein stimulate DCs ex vivo with GM-CSF and simultaneously deliver PAP prostate cancer. This approach restricted by breadth immunity elicited single antigen, cancers that have defined tumor associated antigen. Other multi-antigen approaches been poor efficacy vaccine adjuvants. We developed...
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus co-infections present a heightened COVID-19 disease hospitalization cases. Here, we studied the immunogenicity efficacy of an influenza-A/PR8 virus-like particle ( Flu VLP)-based hybrid vaccine candidate displaying GPI-anchored SARS-CoV-2 receptor binding domain fused to GM-CSF interleukin-12 VLP-RBD) in rhesus macaques. Animals (n=4/group) received two doses either VLP or VLP-RBD four weeks apart were...
e14673 Background: Head and neck cancer exhibits a high degree of heterogeneity, with lack common therapeutic targets. Our phase 1 clinical trial will evaluate novel personalized immunotherapy approach using tumor membrane vesicles (TMV) prepared from the patients’ own surgically excised tissue modifying them by attaching GPI-B7-1 GPI-IL-12 as immune boosting molecules. This vaccine then be administered to boost tumor-specific immunity. We report here feasibility developing an effective...
Abstract Objective The 4T1 triple negative breast cancer (TNBC) model resembles many of the hallmarks advanced TNBC in humans. In this study we investigate if combining a membrane-based immunotherapy with immune checkpoint blockade antibodies metastatic tumor could effectively generate protective immunity. This personalized strategy is applicable to indications such as that exhibit high degree heterogeneity and do not respond approved therapies. Methods tissue was harvested from BALB/c mice...
Abstract Introduction: Head and neck cancer is a leading cause of related deaths accounting for approximately 3% all mortalities in the US. Currently, there no cure advanced squamous cell carcinoma head (SCCHN) thus development efficacious therapies urgently needed. To test whether vaccine-induced immunity inhibits tumor growth, we investigated efficacy membrane-based vaccine immunotherapy murine SCCHN (SCC VII) model. Materials Methods: The SCC VII tumors grown subcutaneously C3H/HeJ mice...
Introduction: Head and neck cancer is a leading cause of related deaths accounting for approximately 3% all mortalities in the US. Currently, there no cure advanced squamous cell carcinoma head (SCCHN) thus development efficacious therapies urgently needed. To test whether vaccine-induced immunity inhibits tumor growth, we investigated efficacy membrane-based vaccine immunotherapy murine SCCHN (SCC VII) model.Materials Methods: The SCC VII tumors grown subcutaneously C3H/HeJ mice were...